Literature DB >> 16284570

Mutations in apoptosis-related gene, PDCD10, cause cerebral cavernous malformation 3.

Bulent Guclu1, Ali K Ozturk, Katie L Pricola, Kaya Bilguvar, Dana Shin, Brian J O'Roak, Murat Gunel.   

Abstract

OBJECTIVE: To identify the CCM3 gene in a population of 61 families with a positive family history of cerebral cavernous malformations (CCM), 8 of which had suggestive linkage to the CCM3 locus.
METHODS: We searched for mutations within the CCM3 interval using a high-throughput screening technique, temperature-gradient capillary electrophoresis. Mutations detected by this device were subsequently sequenced, and the results were analyzed.
RESULTS: A recent study by Bergametti et al. established Programmed Cell Death 10 (PDCD10) as the gene responsible for CCM3. We hereby confirm PDCD10 as the CCM3 gene by reporting four novel mutations in 61 CCM families. Two of these mutations were identical and produced a stop codon in exon 7. Another two resulted in frameshift mutations in exon 6, although the mutations occurred at different points along the exon. The last mutation caused a frameshift in exon 9. Of note, mutations in these families completely cosegregated with the trait. Three of the five families had prior linkage data suggestive of the CCM3 locus, whereas the remaining two were identified in index patients with a positive family history but no linkage data.
CONCLUSION: Our data establish PDCD10 as the gene responsible for CCM in families linking to the CCM3 locus. The discovery of the third gene involved in inherited forms of CCM, after KRIT1 and Malcavernin, is an important step toward dissecting the molecular pathophysiology of this disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284570     DOI: 10.1227/01.neu.0000180811.56157.e1

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  43 in total

1.  Molecular recognition of leucine-aspartate repeat (LD) motifs by the focal adhesion targeting homology domain of cerebral cavernous malformation 3 (CCM3).

Authors:  Xiaofeng Li; Weidong Ji; Rong Zhang; Ewa Folta-Stogniew; Wang Min; Titus J Boggon
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

2.  Phosphorylation sites in the cerebral cavernous malformations complex.

Authors:  Jaehong Kim; Nicholas E Sherman; Jay W Fox; Mark H Ginsberg
Journal:  J Cell Sci       Date:  2011-12-01       Impact factor: 5.285

Review 3.  Brain endothelial cell death: modes, signaling pathways, and relevance to neural development, homeostasis, and disease.

Authors:  Maria Teresa Rizzo; H Anne Leaver
Journal:  Mol Neurobiol       Date:  2010-04-21       Impact factor: 5.590

4.  Multiple cerebral cavernous malformations and a novel CCM3 germline deletion in a German family.

Authors:  Chi-un Choe; Florence Riant; Christian Gerloff; Elisabeth Tournier-Lasserve; Michael Orth
Journal:  J Neurol       Date:  2010-07-11       Impact factor: 4.849

5.  Systems biology and proteomic analysis of cerebral cavernous malformation.

Authors:  Alexander R Edelmann; Sarah Schwartz-Baxter; Christopher F Dibble; Warren C Byrd; Jim Carlson; Ivandario Saldarriaga; Sompop Bencharit
Journal:  Expert Rev Proteomics       Date:  2014-03-31       Impact factor: 3.940

6.  CCM1 gene deletion identified by MLPA in cerebral cavernous malformation.

Authors:  Sabine Gaetzner; Sonja Stahl; Oguzkan Sürücü; Anne Schaafhausen; Birgit Halliger-Keller; Helmut Bertalanffy; Ulrich Sure; Ute Felbor
Journal:  Neurosurg Rev       Date:  2006-12-23       Impact factor: 3.042

Review 7.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

Review 8.  Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling.

Authors:  Bryan T Richardson; Christopher F Dibble; Asya L Borikova; Gary L Johnson
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

9.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

10.  Advanced magnetic resonance imaging of cerebral cavernous malformations: part I. High-field imaging of excised human lesions.

Authors:  Robert Shenkar; Palamadai N Venkatasubramanian; Jin-cheng Zhao; H Hunt Batjer; Alice M Wyrwicz; Issam A Awad
Journal:  Neurosurgery       Date:  2008-10       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.